GlassScriptPhysician profile
Blair Ezbicki
NPI 1326497140
$7,296.04
in general payments reported to CMS, 2019-2025
29 companies · $597 in 2025
The $597 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,511 · 2022: $1,814 · 2023: $1,203 · 2024: $2,172 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278 · Travel and Lodging: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.91 |
| Travel and Lodging | $693.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,734.39 | 2021-2025 | Linq II, Cobalt Dr Mri Surescan, Venaseal |
| Janssen Pharmaceuticals, INC | $864.07 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $738.57 | 2021-2025 | |
| Boston Scientific Corporation | $677.00 | 2022-2025 | Watchman Access System, Watchman Flx, Resonate El Icd Vr |
| Pfizer INC. | $604.39 | 2021-2025 | |
| Abbott Laboratories | $365.65 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet, Aveir |
| E.R. Squibb & Sons, L.L.C. | $335.58 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $254.57 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $243.30 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $217.13 | 2021-2025 | |
| Novo Nordisk INC | $171.36 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $161.46 | 2022-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.46 | 2021-2022 | |
| Astellas Pharma US INC | $99.30 | 2021 | |
| United Therapeutics Corporation | $90.94 | 2024 | Tyvaso |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.78 | 2022-2024 | Verquvo |
| Cvrx, INC. | $66.85 | 2023-2025 | Barostim Neo System |
| Biosense Webster, INC. | $64.55 | 2021 | |
| Atricure, INC. | $55.87 | 2022 | |
| Esperion Therapeutics, INC. | $47.13 | 2021-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $43.27 | 2021 | |
| Agepha Pharma Fz LLC | $39.52 | 2024 | Lodoco |
| Sobi, INC | $36.75 | 2021 | |
| Genzyme Corporation | $29.89 | 2021-2024 | |
| Amarin Pharma, INC. | $26.64 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.77 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $24.29 | 2024 | Opsumit |
| Alnylam Pharmaceuticals INC. | $20.35 | 2023 | Onpattro |
| Irhythm Technologies, INC. | $18.21 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blair Ezbicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.